New and recently funded Medical Startups
1
Country: USA | Funding: $135.5M
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
2
Country: Australia | Funding: $12.1M
Baymatob is developing an AI-powered maternal-foetal early warning platform. Its flagship device Oli uses sensors and AI to identify mothers who are at high risk of developing abnormal postpartum haemorrhage (PPH) before giving birth.
Baymatob is developing an AI-powered maternal-foetal early warning platform. Its flagship device Oli uses sensors and AI to identify mothers who are at high risk of developing abnormal postpartum haemorrhage (PPH) before giving birth.
3
Country: Australia | Funding: $18.7M
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
4
Country: China | Funding: $250M
Syneron leverages AI through its proprietary Synova macrocyclic peptide platform. The company describes macrocyclic peptides as a “goldilocks” drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. Using this technology Syneron develops a pipeline across multiple indications in oncology, autoimmune, metabolic and rare disease programs.
Syneron leverages AI through its proprietary Synova macrocyclic peptide platform. The company describes macrocyclic peptides as a “goldilocks” drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. Using this technology Syneron develops a pipeline across multiple indications in oncology, autoimmune, metabolic and rare disease programs.
5
Country: USA | Funding: $121.5M
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
6
Country: USA | Funding: $15.6M
Insight Health is a clinical AI agent platform that automates patient communication and clinical documentation for medical practices.
Insight Health is a clinical AI agent platform that automates patient communication and clinical documentation for medical practices.
7
Country: USA | Funding: $300M
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
8
Country: Serbia
DeepDoctor MedTech Company's flagship product is DeepDoctor PRO, an AI-based physician's assistant that supports rapid generation of differential diagnoses in a structured clinical format.
DeepDoctor MedTech Company's flagship product is DeepDoctor PRO, an AI-based physician's assistant that supports rapid generation of differential diagnoses in a structured clinical format.
9
Country: Switzerland | Funding: $200M
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
10
Country: USA | Funding: $20M
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
